Genmab reported DKK10.38B in Cash and Equivalent for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Agios Pharmaceuticals AGIO:US USD 122.45M 33.91M
Amarin AMRN:US USD 240.5M 12.5M
Amgen AMGN:US USD 9.5B 4.3B
Artemis Alpha ATS:LN GBP 2.39M 4.76M
AstraZeneca AZN:LN USD 4.46B 359M
Bayer BAYN:GR EUR 4.36B 949M
Biomarin Pharmaceutical BMRN:US USD 761.52M 141.71M
Bluebird Bio BLUE:US USD 66.48M 15.02M
Exelixis EXEL:US USD 675.29M 48.29M
Fresenius Medical Care FME:GR EUR 1.11B 89M
Genmab GEN:DC DKK 10.38B 561M
GlaxoSmithKline GSK:LN GBP 3.61B 2.86B
GN Store Nord GN:DC DKK 870M 310M
Hikma Pharmaceutical HIK:LN USD 23M 1000K
Immunogen IMGN:US USD 309.51M 64.36M
Insmed INSM:US USD 414.63M 1.44M
Lonza Group LONN:SW CHF 1.53B 56M
Merck MRK:GR EUR 1.6B 24M
Novartis NOVN:VX USD 8.73B 5.1B
Regeneron Pharmaceuticals REGN:US USD 3.49B 96.2M
Seattle Genetics SGEN:US USD 362.6M 2.27M